Charles (Chip) R. Romp is currently Chief Executive Officer of Secura Bio, an integrated, commercial-stage pharmaceutical company dedicated to the worldwide development and commercialization of oncology therapies, where he served as Chief Executive Officer since October 2024. Mr. Romp previously served as Executive Vice President, Commercial U.S., at Seagen Inc., where he was a member of the Executive Committee and oversaw the company s entire commercial organization before its sale to Pfizer. He joined Seagen in 2010 as one of its first commercial employees, where he managed the growth and expansion of ADCETRIS (brentuximab vedotin), PADCEV (enfortumab vedotin-ejfv), TUKYSA (tucatinib) and TIVDAK (tisotumab vedotin-tftv). Prior to Seagen, Mr. Romp held several senior sales leadership positions at Genentech, Inc., where he was responsible for both oncology and immunology products, including AVASTIN (bevacizumab), RITUXAN (rituximab) and XOLAIR (omalizumab). Mr. Romp received a Bachelor of Arts from the University of Florida and an MBA from Saint Leo University in Florida. Among other attributes, skills and qualifications, the Board believes Mr. Romp is uniquely qualified to serve as a director because of his deep experience commercializing significant oncology drugs.